Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) has announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders using its Ella platform. This platform offers high-quality, automated immunoassays with results delivered in 90 minutes using only 25 µL of sample. Under the collaboration, Ella instruments will be provided for clinical trials in India, aiming for regulatory approval as a diagnostic device. Executives highlighted Ella's potential to enhance diagnostics in ophthalmology.

Positive

• Collaboration with Narayana Nethralaya expands Ella's diagnostic capabilities.
• Ella platform automates immunoassays, reducing manual intervention.
• Plans for clinical trials in India may lead to regulatory approval.

Negative

• None.

MINNEAPOLIS, May 18, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ella platform, which is currently sold for research use only, allows users to perform high-quality immunoassays with no manual intervention, delivering results in just 90 minutes and requiring only 25 µL of sample. Factory calibration of each Simple Plex assay cartridge minimizes setup time and user error. Setting up an assay simply requires loading diluted samples into the cartridge. Once loaded, Ella performs every step of the immunoassay automatically, from wash steps to final quantification of results.

Under the terms of this collaboration, Bio-Techne will provide Ella instruments and Simple Plex assay cartridges, which are run on the Ella platform, for customized ophthalmology related evaluations. Narayana Nethralaya plans to conduct diagnostic clinical trials in India, with the aim of filing for regulatory approval using Ella as a diagnostic device for ophthalmic applications.

"This collaboration with Narayana Nethralaya potentially expands Ella's capabilities as a tool for diagnosing ophthalmology disorders in India," commented Chuck Kummeth, Bio-Techne's President and Chief Executive Officer.  "We believe Ella has great potential as a clinical diagnostic system and look forward to pursuing these applications in the future."

"The use of Ella during the diagnostic development process provides significant benefits over manual ELISA based approaches, enabling faster biomarker screening," commented Dr. Arkasubhra Ghosh, Director of GROW Laboratory at Narayana Nethralaya.. "We are excited to utilize Ella to provide a better solution for differential diagnosis and monitoring of patients with ophthalmic disorders", said Dr. Rohit Shetty, Narayana Nethralaya's Vice-Chairman.

More information on ELLA can be found at
https://www.proteinsimple.com/ella.html

About Bio-Techne Corporation (NASDAQ: TECH)

Investor Relations

Contact: David Clair, Senior Director, Investor Relations and Corporate Development
Phone: 612-656-4416
Email: david.clair@bio-techne.com

About Narayana Nethralaya
Established in the year 1982 as an eye clinic at Srirampuram, Bangalore, by Dr. K. Bhujang Shetty, a leading luminary in the field of ophthalmic health care, Narayana Nethralaya has achieved remarkable growth in the last 39 years, becoming one of the top tertiary eye hospitals serving close to half a million patients annually. A testimony to his determination and hard work, Dr. Shetty's vision of establishing a 'dream center' of service, eye care training, personalised treatments and research is now a reality.

For more information visit https://www.narayananethralaya.org

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications-301293276.html

SOURCE Bio-Techne Corporation

FAQ

What is the recent collaboration announced by Bio-Techne (TECH)?

Bio-Techne announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders using the Ella platform.

How does the Ella platform improve ophthalmic diagnostics?

The Ella platform automates immunoassays, providing results in just 90 minutes with minimal sample requirements, which enhances diagnostic efficiency.

What are the goals of the collaboration with Narayana Nethralaya?

The collaboration aims to conduct clinical trials in India and seeks regulatory approval for Ella as a diagnostic device for ophthalmic applications.

What are the key features of the Ella platform?

The Ella platform performs automated immunoassays, requires only 25 µL of sample, and minimizes user error through factory calibration.